High Potency APIs Market / HPAPI Market worth $39.6 billion by 2027

Posted April 10, 2024 by mmvaidya01

The global high potency APIs market in terms of revenue was estimated to be worth $24.5 billion in 2022 and is poised to grow at a CAGR of 10.1% from 2022 to 2027.

Market Size Estimation:

The research methodology used to estimate the market size includes the following details:

# The key players in the market were identified through secondary research, and their market contributions were determined through primary and secondary research.
# This entire procedure included the study of the annual and financial reports of the top market players and extensive interviews for the key insights from industry leaders.
# All percentage shares, splits, and breakdowns were determined by secondary sources and verified through primary sources.
# All possible parameters affecting the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to reach the final quantitative and qualitative data.
# The data mentioned above is consolidated and added with detailed inputs and analyses from MarketsandMarkets and presented in this report.

Projected Surge in Revenue Generation:

The global HPAPI market is projected to reach USD 39.6 billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027.

Major Growth Boosting Factors:

The demand for oncology medications, antibody-drug conjugates, top pharmaceutical firms' expanding emphasis on HPAPIs, improvements in HPAPI manufacturing methods, and an increasing emphasis on precision medicine are some of the drivers propelling this market's expansion.

Download PDF Brochure@

Data Triangulation:

After arriving at the overall market size, the total market was split into several segments and subsegments. To complete the overall market engineering process and to arrive at the exact statistics for all the segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides. Along with this, the market was validated using both top-down and bottom-up approaches.

The Oncology segment is expected to account for the largest share of the market in 2021.

On the basis of therapeutic application, the market is segmented into oncology, hormonal imbalance, glaucoma, and other therapeutic applications. The oncology segment is expected to account for the largest share of the global market in 2018. The growing incidence and prevalence of cancer across the globe and the launch of new target therapies in addition to technological advancements in the oncology HPAPI-antibody conjugate technology are major factors contributing to the growth of this segment.

Geographical Growth Scenario:

The Asia region is the fastest-growing region of High Potency APIs/HPAPI Market from 2022 to 2027

North America, Europe, Asia, and the Rest of the World (RoW) comprise the segments of the HPAPI market. Throughout the projection period, Asia is anticipated to grow at the fastest rate. The Asian market is expanding due to a number of factors, including the aging population, the high prevalence of chronic and lifestyle diseases, the rise in disposable income, the prevalence of age- and lifestyle-related diseases, government initiatives to improve healthcare and promote the use of generics, and the region's expanding market for merchant manufacturers because of its low labor and manufacturing costs.

Global Key Players:

The major players in the HPAPI market include Pfizer Inc. (US), Novartis International AG. (Switzerland), Sanofi (France), Hoffmann La-Roche (Switzerland), and Bristol Myers Squibb Company (US).

Request Sample Pages@

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Makarand Vaidya
Country United States
Categories Biotech , Industry , Research
Tags high potency apis , high potency apis market , hpapi market
Last Updated April 10, 2024